Transplantation and Cellular Therapy

Sustained Efficacy and Safety in Adult and Pediatric Patients with Transfusion-Dependent ß-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel).

Mark C. Walters, Alexis A. Thompson, Timothy S. Olson, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Ge Tao, Himal L. Thakar, Ami Deora, Katiana Gruppioni, Richard A. Colvin, Franco Locatelli, Janet L. Kwiatkowski

385 Long-term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed-up to 7 Years after Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy (GT) and Factors Impacting Neutrophil and Platelet Engraftment.

Transplantation and Cellular Therapy

Timothy S. Olson, Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson

28 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel) Gene Therapy in 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT): 7-Year Post-Infusion Follow-up of Phase 1/2 and Phase 3 Studies.

Transplantation and Cellular Therapy

Jennifer Schneiderman, Franco Locatelli, Alexis A. Thompson, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Manfred Schmidt, Lin Du, Richard A. Colvin, Mark C. Walters

Northern California Comprehensive Thalassemia Center

Search form

You are here

Sustained Efficacy and Safety in Adult and Pediatric Patients with Transfusion-Dependent ß-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel).

385 Long-term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed-up to 7 Years after Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy (GT) and Factors Impacting Neutrophil and Platelet Engraftment.

28 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel) Gene Therapy in 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT): 7-Year Post-Infusion Follow-up of Phase 1/2 and Phase 3 Studies.